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Abstract
Background: Binding of the programmed death-1 (PD-1) receptor to its ligands (PD-L1/2) transduces inhibitory
signals that promote exhaustion of activated T cells. Blockade of the PD-1 pathway is widely used for cancer
treatment, yet the inhibitory signals transduced by PD-1 in T cells remain elusive.
Methods: Expression profiles of human CD8+ T cells in resting, activated (CD3 + CD28) and PD-1-stimulated cells
(CD3 + CD28 + PD-L1-Fc) conditions were evaluated by RNA-seq. Bioinformatic analyses were used to identify
signaling pathways differentially regulated in PD-1-stimulated cells. Metabolic analyses were performed with
SeaHorse technology, and mitochondrial ultrastructure was determined by transmission electron microscopy. PD-1-
regulated mitochondrial genes were silenced using short-hairpin RNA in primary cells. Blue native gel
electrophoresis was used to determine respiratory supercomplex assembly.
Results: PD-1 engagement in human CD8+ T cells triggers a specific, progressive genetic program different from
that found in resting cells. Gene ontology identified metabolic processes, including glycolysis and oxidative
phosphorylation (OXPHOS), as the main pathways targeted by PD-1. We observed severe functional and structural
alterations in the mitochondria of PD-1-stimulated cells, including a reduction in the number and length of
mitochondrial cristae. These cristae alterations were associated with reduced expression of CHCHD3 and CHCHD10,
two proteins that form part of the mitochondrial contact site and cristae organizing system (MICOS). Although PD-
1-stimulated cells showed severe cristae alterations, assembly of respiratory supercomplexes was unexpectedly
greater in these cells than in activated T cells. CHCHD3 silencing in primary CD8+ T cells recapitulated some effects
induced by PD-1 stimulation, including reduced mitochondrial polarization and interferon-γ production following T
cell activation with anti-CD3 and -CD28 activating antibodies.
Conclusions: Our results suggest that mitochondria are the main targets of PD-1 inhibitory activity. PD-1
reprograms CD8+ T cell metabolism for efficient use of fatty acid oxidation; this mitochondrial phenotype might
explain the long-lived phenotype of PD-1-engaged T cells.
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Background
Programmed death-1 (PD-1; CD279) acts as a negative
regulator of the immune response at the effector phase.
PD-1 transmits inhibitory signals in T cells after inter-
action with its ligands, PD-L1 (B7-H1; CD274) and PD-L2
(B7-DC; CD273). The PD-1/PD-L1/2 system is central to
the maintenance of peripheral tolerance by preventing the
activation of autoreactive T cells that escape from central
tolerance-mediated deletion [1]. High PD-L1/2 levels in
non-hematopoietic tissues are associated with suppression
of tissue-reactive T cells [2].
Chronic exposure to antigen, as occurs in some infec-
tions and most cancers, results in progressive loss of
antigen-specific T cell effector capacity, a phenomenon
termed exhaustion [3]. Exhausted T cells are character-
ized by the expression of inhibitory receptors including
PD-1. An inverse correlation was reported between T
cell function and PD-1 expression levels [4], which has
been exploited therapeutically. Immunotherapy based on
antibodies that neutralize PD-1 or its ligand PD-L1
effectively restores exhausted T cell-mediated anti-tumor
responses in a variety of advanced cancers in humans,
with durable effects and high efficacy compared with
standard cancer treatments [5].
Despite extensive clinical use of PD-1-based therapeu-
tics, little is known of the mechanisms that underlie PD-
1-induced T cell exhaustion. PD-1-mediated inhibition
relies on the immunoreceptor tyrosine-based inhibition
motif (ITIM) and the immunoreceptor tyrosine-based
switch motif (ITSM) in the PD-1 cytoplasmic tail [6].
PD-1 binding to its ligands leads to tyrosine phosphoryl-
ation of a residue in its ITSM, which acts as a docking
site for recruitment of the Src homology region 2
domain-containing phosphatase-2 (SHP-2, encoded by
the PTPN11 gene). PD-1 can also recruit the tyrosine
phosphatase SHP-1 (encoded by the PTPN6 gene), but
only SHP-2 colocalizes with PD-1 and the TCR at the
immune synapse [7]. SHP-2 recruitment to activated
PD-1 is postulated to cause dephosphorylation of TCR-
induced signaling intermediates such as ZAP70 [6, 7].
Regardless of its tyrosine phosphatase activity, SHP-2
positively regulates various signaling cascades [8, 9],
including extracellular signal-regulated kinase (ERK)
activation following TCR triggering [10, 11]. A recent
report showed that SHP-2 is totally dispensable for PD-1
signaling and T cell exhaustion in vivo [12].
PD-1 also targets metabolic reprogramming in CD4+
and CD8+ T cells. Resting and memory T cells typically
use an oxidative metabolic program (OXPHOS) charac-
terized by increased mitochondrial fatty acid oxidation
and spare respiratory capacity (SRC) [13, 14]. In con-
trast, effector T cells rewire their metabolism to potenti-
ate aerobic glycolysis, which triggers proliferation and
expression of effector cytokines such as interferon-
gamma (IFNγ). Mitochondrial function and integrity are
nonetheless critical for both effector and memory phases
of T cell differentiation [15].
In vitro studies show that PD-1 stimulation reduces
the extracellular acidification rate (ECAR) as well as
basal and stimulated O2 consumption rates (OCR),
which indicates that PD-1 engagement dysregulates both
glycolytic and mitochondrial energetics in activated T
cells [16]. Similar metabolic alterations are observed in
vivo in exhausted virus-reactive and tumor-infiltrating
lymphocytes (TIL) [17–19]. Whereas PD-1-mediated
suppression of glycolysis might be caused by abrogation
of the AKT and mTOR pathways downstream of the
TCR [16, 20], the mechanisms by which PD-1 affects
mitochondria are mainly unknown.
To investigate the PD-1-elicited signaling pathways
that cause T cell dysregulation, we analyzed the expres-
sion profiling of human CD8+ T cells in conditions that
mimic simultaneous engagement of PD-1 and the TCR/
CD3 complex. We show here that PD-1 engagement
triggers a specific, time-dependent genetic program dif-
ferent from that in resting cells. This finding suggests
that in addition to blocking TCR-mediated signals, PD-1
can generate specific signaling pathways that dysregulate
T cell function. We provide a mechanistic framework
that explains the reduction in the number and length of
mitochondrial cristae in PD-1-engaged cells, which in-
volves reduced expression of two proteins that form part
of the MICOS complex.
Methods
For a more detailed description, see Additional file 1.
Cell culture and T cell activation
Human embryonic kidney (HEK)-293 T cells (ATCC)
were cultured in DMEM (BioWest). Peripheral blood
mononuclear cells (PBMC) were obtained from buffy
coats from healthy donors (Centro de Transfusiones of
the Comunidad de Madrid, Spain), using Ficoll density
gradients. CD8+ T cells were isolated by negative selec-
tion (EasySep human CD8+ T cell, Stem Cell Technolo-
gies; 86–95.5% purity), and cultured in RPMI-1640
medium (BioWest).
For activation, CD8+ T cells were incubated (1:3.5
ratio) with tosyl-activated magnetic beads (Dynabeads
M-450; Thermo Scientific) coated with 8% anti-CD3
(HIT3a, BD Biosciences), 10% anti-CD28 (CD28.2,
BioLegend), and 82% control IgG1 (TACT), or with anti-
CD3, anti-CD28, and 82% PD-L1-Fc chimeric protein
(R&D Systems) (TACT + PD1); IgG1-coated beads were
used as control (TCTRL). In some experiments, PD-L1-Fc
was used at 16.4, 3.3% or 0.66%. In some experiments,
CD8+ T cells were incubated with TACT + PD1 beads (48 h,
37 °C), which were mechanically released, removed with
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a magnet, and the cells restimulated with TACT or TCTRL
beads (48 h, 37 °C). As positive control, naïve CD8+ T
cells were incubated (48 h, 37 °C) with plate-bound anti-
CD3 (5 μg/ml; UCHT1, BD Biosciences) and soluble
anti-CD28 (2 μg/ml) antibodies.
T cell activation was confirmed by FACS (Cytomics
FC500 or Gallios cytometers; Beckman Coulter) using
anti-CD25-PE (B1.49.9, Beckman-Coulter), −CD279-
APC (MIH4, eBioscience), −CD69-PCy5 (TP1.553,
Inmunotech), and -CD8-FITC (B9.11, Beckman-Coulter)
antibodies. IFNγ was detected by intracellular staining
using anti-IFNγ-PE (B27, Pharmingen) antibody in
permeabilized cells (Beckman-Coulter) pretreated with
brefeldin A (10 μg/ml, 4 h, 37 °C; eBioscience). Dead cells
were detected with propidium iodide (2.5 μg/test, 1 min),
or the LIVE/DEAD stain kit (Invitrogen). Appropriate
isotypes were used as negative controls. Data were ana-
lyzed using Kaluza and FlowJo software.
hCD8+ T cell proliferation was determined by
[methyl-3H] thymidine (1 μCi/well; Perkin Elmer) in-
corporation into DNA, in a 1450 Microbeta liquid
scintillation counter (Perkin Elmer).
RNA-seq analysis
The RNA-seq libraries were prepared using an Illumina
TruSeq Stranded Total RNA Sample Preparation kit
(Illumina). Library size and quality was assessed in an
Agilent DNA 7500 Bioanalyzer assay (Agilent). Each
library was sequenced using TruSeq SBS Kit v3-HS, in
paired end mode with read length 2 × 76 bp. On average,
we generated 36 million paired-end reads for each
sample in a fraction of a sequencing lane on HiSeq2000
(Illumina). Image analysis, base calling, and quality
scoring of the run were processed by Real Time Analysis
(RTA 1.13.48) software, followed by generation of
FASTQ sequence files by CASAVA 1.8.
RNA-seq reads were aligned with the human reference
genome (gencode v19) using the GEMtools RNA-seq
pipeline v1.7 (http://gemtools.github.io), which is based
on the GEM mapper [21]. Expression quantification at
the gene level was calculated with Flux (http://sammeth.
net/confluence/display/FLUX/Home). RNA-seq data
were analyzed using the DESeq2 R Bioconductor pack-
age [22]. Raw counts of sequencing reads were normal-
ized to the effective library size. Real-time quantitative
PCR (qPCR) was performed in an ABI PRISM7900HT
system (Applied Biosystems) with indicated primers
(Additional file 2: Table S1).
A likelihood ratio test (LRT) was used to test for
differences over multiple time points. This test compares
a full model, including an interaction term class:time,
with a reduced model without the interaction term; this
permits to determine whether PD-1 treatment induces
change of a specific gene at any point after time 0. This
class-specific effect is measured as a p value for inter-
action (pinter) and FC values for TACT + PD1 vs. TACT cells
at each time point. Genes with a significant pinter were
analyzed by STEM (Short Time-series Expression
Miner) software [23] for cluster analysis and integration
with the Gene Ontology (GO) database (http://geneonto
logy.org/). These genes were analyzed for enrichment in
KEGG signaling pathways using the online tool
Webgestalt (http://www.webgestalt.org). Genes involved
in metabolic pathways (KEGG hsa011000) were further
explored for known interactions using Cytoescape
(http://www.cytoscape.org/). GO enrichment analysis
was performed using BINGO. GO categories were
summarized and visualized using ClueGO or
REVIGO.
Metabolic assays
Cellular oxygen consumption (OCR) and extracellular
acidification rates (ECAR) were determined in Seahorse
XF Base Medium supplemented with 25mM glucose
(Sigma-Aldrich), 2 mM L-glutamine and 1mM sodium
pyruvate (both from BioWest) using the XF cell Mito
Stress Kit (SeaHorse Bioscience), in an XF24 Extracellu-
lar Flux Analyzer (SeaHorse Bioscience; Agilent Tech-
nologies). Fatty acid oxidation (FAO) was determined in
Krebs-Henseleit buffer (KHB) supplemented with 0.5
mM carnitine (Sigma-Aldrich) and 2.5 mM glucose,
using palmitate as substrate, in the Agilent Seahorse
XF96 Extracellular Flux Analyzer.
Lactate levels were determined enzymatically in ex-
tracts from TCTRL, TACT and TACT + PD1 cells after 48 h
stimulation, using a fluorometric lactate assay kit (Cell
Biolabs) according to supplier’s protocol; fluorescence
was quantified in a Filter Max F5 microplate reader
(Molecular Devices) at 530/590 nm excitation/emission.
A lactate standard curve was generated in all assays and
used to extrapolate relative fluorescent units (RFU)
measured in the samples.
Blue native and immunoblot analyses
Equal amounts of Triton X-100-based cells lysed were
analyzed by SDS-PAGE analysis and immunoblotted
with specific antibodies (see Additional file 1) [24]. For
blue native analyses, we obtained a mitochondria-enriched
fraction by cell lysis with hypotonic buffer and
homogenization with a polypropylene pestle homogenizer.
Nuclei and unbroken cells were removed, and mitochon-
dria obtained by centrifugation (12,000×g) from the
cytosolic fraction. The enriched mitochondrial fraction
was suspended in 50mM Tris-HCl pH 7.0 containing 1M
6-aminohexanoic acid, lysed in 10% digitonin at 4 g/g
mitochondrial proteins, and mitochondrial proteins frac-
tionated in blue native gels.
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Functional and structural mitochondria studies
Total mitochondrial mass, mitochondrial membrane
potential (ΔΨm) and reactive oxygen species (ROS) were
determined by FACS using MitotrackerGreen FM, tetra-
methylrhodamine, methyl ester (TMRM) and MitoSOX
probes (Thermo Fisher), respectively. DNP (2,4-dinitro-
phenol) was used as ΔΨm negative control. Dead cells
were excluded by diamino-2-phenylindol (DAPI) stain-
ing. Mitochondrial DNA (mtDNA) was extracted from
hCD8+ cells with the DNeasy Blood and Tissue kit (Qia-
gen) and quantified by RT-qPCR using primers for MT-
TL1 tRNA (Leu)(UUR) [25]; the α2-microglobulin gene
was used for normalization.
Immunofluorescence analyses were performed in
paraformaldehyde-fixed CD8+ T cells, permeabilized
with Triton X-100 (0.1%). After blocking, cells were
stained sequentially with anti-human aconitase-2
(6F12BD9, Abcam) and goat anti-mouse Alexa 488 (Mo-
lecular Probes). Samples were mounted in Prolong Gold
Antifade Reagent with DAPI (Cell Signaling) and images
captured in a Leica Microsystems microscope (LAS X
v2.01; 60x objective). Mitochondrial morphology was
determined with ImageJ [26].
For transmission electron microscopy, fixed cells were
treated sequentially with 1% osmium tetroxide (TAAB
Laboratories) and 2% aqueous uranyl acetate, dehydrated
with acetone, embedded in EPON 812 resin, and poly-
merized. Ultrathin sections (70 nm-thick; Ultracut EM
UC6, Leica Microsystems) in 200 mesh nickel EM grids
(Gilder) were stained with 3% aqueous uranyl acetate
and lead citrate, and analyzed on a JEOL JEM 1011 elec-
tron microscope. The number of mitochondria per cell
and cristae length were quantified by two independent
observers blind to the experiment.
CHCHD3 silencing experiments
Lentiviruses encoding CHCHD3 or control short hairpin
RNA (shRNA; Genecopoeia) were produced in HEK-
293 T cells. Prior to transduction, hCD8+ cells were
stimulated with anti-CD3- and -CD28 antibody-coated
beads, then transduced with viral supernatants at 10–20
m.o.i in the presence of polybrene. CHCHD3 silencing
was determined by qPCR and by immunoblot.
Statistical analysis
Normal or parametric distribution of the data was
analyzed. For comparison between two conditions, data
were analyzed with the Mann-Whitney U test. For
multiple non-parametric comparisons, Kruskal-Wallis
followed by Dunn’s post-test was used. For multiple
parametric comparisons, data were analyzed by one- or
two-way ANOVA with the Bonferroni post-hoc test. For
the same samples with different treatments, paired
Student’s t-test was performed for two comparisons or
paired repeated-measures one-way ANOVA for more
than two conditions. Differences were considered signifi-
cant when p < 0.05. All statistical analyses were per-
formed using Prism 7.0 software (GraphPad).
Results
RNA-seq distinguishes specific PD-1-induced gene sets in
human CD8+ T cells
To determine how PD-1 signals change gene expression
during activation of human (h)CD8+ T cells, we used an
in vitro system that mimics the simultaneous engage-
ment of PD-1 and the TCR/CD3 complex. Purified
hCD8+ T cells were stimulated with magnetic beads con-
jugated with stimulating anti-CD3 and -CD28 antibodies
(TACT cells), or with anti-CD3, anti-CD28, and PD-L1-Ig
fusion protein (TACT + PD1 cells); hCD8
+ T cells incu-
bated 6 h with polyclonal IgG-conjugated beads were
used as control (TCTRL cells). In these conditions, PD-1
consistently inhibited hCD8+ T cell activation and
effector functions, determined by a reduction in CD25,
CD69 and IFNγ expression (Fig. 1a-d), as well as de-
creased proliferation (Fig. 1e). The PD-1-induced reduc-
tion was dose-dependent (Additional file 3: Figure S1).
Total RNA was isolated from TCTRL, TACT and TACT +
PD1 at 6, 24 and 48 h post-stimulation, and gene expres-
sion analyzed by RNAseq. MA plots representing log2-
fold changes (FC) against mean normalized counts were
generated for all experimental conditions (Add-
itional file 4: Figure S2; red dots indicate significant
genes with a 10% false discovery rate (FDR)). Principal
components analysis (PCA; Fig. 1f ) and hierarchical
clustering of the top 200 most-variable genes across
samples (Fig. 1g) were used to determine similarity
between expression profiles. These analyses clustered
the three biological replicates of TACT cells at each time
analyzed; these analyses also differentiated TACT + PD1
samples after 24 and 48 h stimulation from the TCTRL
and TACT + PD1 after 6 h stimulation, which were very
close or intermixed. Venn diagrams showed a number of
unique sets of differentially expressed genes in the
TACT + PD1 cells compared to TCTRL and TACT counter-
parts (Fig. 1h). These results suggest that PD-1 engage-
ment not only prevented hCD8+ T cell activation, but
also triggered a specific transcriptional program in
hCD8+ T cells.
PD-1 engagement impairs expression of metabolic genes
in human CD8+ T cells
We used LRT to identify genes expressed differentially over
time. This type of analysis identifies genetic patterns im-
paired by PD-1 engagement more reliably than direct com-
parison between TCTRL, TACT and TACT+PD1 RNAseq data
at each time point. LRT analysis identified 1651 genes with
divergent expression between TACT and TACT+PD1 (pinter <
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0.05), but only 578 passed FDR correction (Adj-pinter <
0.05); Additional file 5: Table S2 shows the top 20 genes in
this analysis. KEGG pathway analysis using these 578 genes
indicated that, in addition to pathways related to cell cycle
and immune function, there was significant enrichment in
metabolic genes, with 43 genes in this category (Fig. 2a;
Fig. 1 Characterization of gene expression profiles in CD8+ T cells after PD-1 ligation. a Representative dot plots showing CD25 and CD69
staining of primary human CD8+ T cells after 48 h stimulation with TCTRL, TACT, and TACT + PD1 beads. b Quantification of CD25- and CD69-expressing
cells from dot plots as in a. Each dot represents a donor (n = 18). c Representative histograms showing IFNγ production by cells stimulated as in a for
24 and 48 h. d Quantification of data from c (n = 4). e Thymidine ([3H]-TdR) incorporation by cells stimulated as in a (n = 5). f PCA plot using the rlog-
transformed values from the RNA-seq analysis. Each unique combination of cell stimulation and time is assigned a distinct color. g Hierarchical
clustering dendrogram of the top 200 most-variable genes across samples. The heat map color code (left) uses the combination of cell stimulation/
time as in f. h Venn diagrams showing the number of differentially expressed genes between indicated conditions at different times. For d and e, data
show mean ± SEM. ** p < 0.01; *** p < 0.001, one-way (b) or two-way ANOVA (d, e) with Bonferroni post-test
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Additional file 6: Table S3). The primary metabolic pro-
cesses with the most differentially regulated genes were
amino acid, nucleotide and carbohydrate (glycolysis and the
pentose phosphate) metabolism, the citrate cycle and
OXPHOS (Additional file 7: Figure S3).
GO enrichment analysis of the 43 metabolic genes
showed generation of precursor metabolites and en-
ergy and oxidative phosphorylation among the most
represented biological processes (Additional file 8:
Figure S4); the most represented molecular functions
were NADH dehydrogenase and oxidoreductase ac-
tivities (Additional file 9: Figure S5). Mitochondria
and the respiratory chain were also identified as
significantly enriched cellular components (Add-
itional file 10: Figure S6).
PD-1 engagement suppresses glycolysis and oxidative
phosphorylation in CD8+ T cells
To validate the transcriptional changes with metabolic
alterations, we focused on glycolysis and OXPHOS,
key metabolic pathways for T cell differentiation and
function [13, 27]. We found that lactate production, a
glycolysis indicator, was reduced in TACT + PD1 com-
pared with TACT cells, in a dose-dependent manner
(Fig. 2b, c). TACT + PD1 cells similarly showed a signifi-
cant ECAR reduction (Fig. 2d), which suggested that
PD-1 ligation effectively inhibited the glycolytic path-
way in CD8+ T cells. When we used high glucose
levels as an energy source, basal OCR, an OXPHOS
indicator, was significantly higher in TACT than in
TCTRL and TACT + PD1 cells (Fig. 2e); the OCR/ECAR
ratio was nonetheless higher in TACT + PD1 than in
TACT cells (Fig. 2f ), which suggested that TACT + PD1
cells preferentially use OXPHOS rather than glycolysis
to generate ATP.
To analyze additional parameters of mitochondrial
metabolism, we measured OCR in real time in basal
conditions and after addition of several mitochon-
drial inhibitors (Fig. 2g). Addition of FCCP, which
uncouples ATP synthesis from the electron transport
chain, showed that maximal respiration capacity was
higher in TACT than in TCTRL and TACT + PD1 cells
(Fig. 2h). TCTRL and TACT + PD1 cells nonetheless had
a substantial mitochondrial SRC, as indicated by the
difference between maximal and basal OCR (Fig. 2i).
The elevated SRC, a parameter associated with long-
term survival [14], and the higher OCR/ECAR ratio
suggest more efficient OXPHOS in TACT + PD1 than
in TACT cells. Confirming this idea, proton leak (de-
termined as OCR after oligomycin relative to OCR
after rotenone and antimycin A) was significantly
lower in TACT + PD1 than in TACT cells (Fig. 2j); there
was also a tendency to lower proton leak in TACT +
PD1 than in TCTRL cells (Fig. 2j).
To further study metabolic differences in the mito-
chondria of PD-1-stimulated cells, we measured OCR
using palmitate as a substrate, alone or in the pres-
ence of etomoxir, which inhibits carnitine palmitoyl-
transferase 1A (CPT1A), a central enzyme for long-
chain fatty acid oxidation in mitochondria. Etomoxir
led to greater inhibition of basal and maximal (after
oligomycin and FCCP treatment) OCR in TACT + PD1
than in TCTRL and TACT cells (Fig. 2k-n), which
indicated greater OXPHOS dependence on FAO in
TACT + PD1 cells than in the other conditions. We also
found time-dependent induction of CPT1A in TACT +
PD1 compared to TCTRL and TACT cells (Fig. 2o, p),
which might explain the mechanism underlying the
higher FAO capacity of PD-1-stimulated cells. These
results indicate that PD-1 signals reprogram CD8+ T
cell metabolism for efficient use of FAO-dependent
mitochondrial OXPHOS, which resembles some as-
pects of long-lived memory T cells [14]. Moreover,
the distinct FAO-dependent OXPHOS between TCTRL
and TACT + PD1 cells (Fig. 2l, n) suggests that PD-1-
induced metabolic changes are not simply blockade of
T cell activation, but involve unique, time-dependent
programs induced by PD-1 engagement.
(See figure on previous page.)
Fig. 2 PD-1 ligation impairs mainly CD8+ T cell metabolism. a KEGG signaling pathways with the highest scores significantly enriched in the 578
transcripts selected by LRT. b Lactate production in hCD8+ T cells stimulated 48 h with TCTRL, TACT and TACT + PD1 beads. c Lactate production in
hCD8+ T cells stimulated 48 h with TACT + PD1 beads containing the indicated amounts of PD-L1-Fc. d-f hCD8
+ T cells were stimulated with beads
as in b and analyzed with SeaHorse. Basal extracellular acidification rate (ECAR; D), basal O2 consumption rate (OCR; e), and basal OCR/ECAR ratio
(f). g OCR obtained during mitochondrial stress test in cells stimulated as in b, performed by injection of oligomycin, the mitochondrial
uncoupler FCCP, and the electron transport chain inhibitors antimycin A/rotenone. h-j Maximal OCR obtained after FCCP injection (h), spare
respiratory capacity (SRC; i) calculated as the difference between maximal and basal OCR, and relative proton leak (j) determined as OCR after
oligomycin and subsequent injection of rotenone plus antimycin A. k-n hCD8+ T cells were stimulated with beads as in b, treated with etomoxir
or vehicle and analyzed with SeaHorse, using palmitate as substrate. Basal OCR with vehicle (solid) or with etomoxir (hatched) (k), FAO-specific
OCR from data in k (l), maximal OCR after FCCP injection in vehicle or etomoxir-treated cells (m), FAO-specific maximal OCR calculated from m
(n). o Representative immunoblots for CPT1A and β-actin (loading control) in CD8+ T cells stimulated as indicated. p Densitometric analysis of
immunoblots as in o. The CPT1A/β-actin ratio is shown, with the value for TCTRL cells as reference (n = 3 donors). Data are mean ± SEM from six
(b, d-j), four (k-n) or three (p) donors; for c, data are mean ± SD representative of one donor from two. ** p < 0.01, * p < 0.05, Kruskal-Wallis with
Dunn’s post-hoc test for multiple comparisons (b, d-f, h-k, m), two-tailed Student’s t-test (l, n), or two-way ANOVA with Newman-Keuls post-hoc
test for multiple comparisons (p)
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PD-1 ligation reduces mitochondrial polarization and ROS
production
We analyzed mitochondria bioenergetics in live cells by
combining the ΔΨm-sensitive TMRM and the ΔΨm-
independent MitotrackerGreen probes; the depolarizing
agent DNP was used as a TMRM staining control
(Fig. 3a). Compared with TCTRL cells, CD8
+ T cell activa-
tion caused a significant increase in both the number of
cells with polarized mitochondria (Fig. 3b) and the
TMRM fluorescence bound to these mitochondria
(Fig. 3c-d). PD-1 ligation abrogated the ΔΨm increase
caused by activation stimuli (Fig. 3c-d). Reactive
oxygen species (ROS) production nonetheless did not
differ statistically between TACT + PD1 and TACT cells
(Fig. 3e). It appears that although PD-1 affects mitochon-
drial function, these organelles retain some respiratory
capacity compared to that of resting TCTRL cells.
We tested whether the PD-1 effects on ΔΨm were re-
versible. CD8+ T cells were incubated with TACT + PD1
beads and, after PD-L1 washout, stimulated with TACT
or TCTRL beads (Fig. 3f ). Re-stimulation of TACT + PD1
with TCTRL beads indicated that pre-incubation of cells
with PD-L1 reduced both the percentage of cells with
polarized mitochondria as well as TMRM fluorescence
intensity compared to TACT cells. But more important,
after re-stimulation with TACT beads, the PD-L1-
preincubated cells did not recover either the percentage
of TMRM+ cells or fluorescence intensity to the levels
observed in primary TACT cells (Fig. 3g, h). These results
suggest that PD-1 effects on these mitochondrial param-
eters were irreversible.
PD-1 controls expression of genes involved in
mitochondrial structure and function
Of the 578 genes selected by LRT, 84 coded for tran-
scripts enriched in mitochondrial-related GO categories
(Additional file 11: Figure S7). These 84 genes were not
only related to metabolic pathways, but also included
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as negative control. b Time-dependent expansion of TMRM+ cells after indicated stimuli (n = 5). c Representative histograms of TCTRL, TACT and
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those involved in mitochondrial DNA replication and
repair (FEN1, TOP2A, XRCC3), translation (POP7,
MRPL39, MRPS12), protein import machinery
(TIMM22, TIMM23, TOMM34), fusion/fission (MIEF1,
MTCH1), cristae structure and organization (CHCHD3,
CHCHD10, HSPA9), and assembly of protein complexes
of the respiratory chain (ATP5G1, COX8A, NDUFB3,
SELRC1, UQCRC2) (Additional file 12: Table S4).
We used STEM software [23] to analyze and cluster
our gene expression dataset more stringently. STEM
clustering of logFC values generated eight model expres-
sion profiles significantly enriched (FDR < 0.05) for tran-
scripts expressed longitudinally in TACT vs TACT + PD1
cells (Fig. 4a). Profile A, which clustered transcripts
whose expression increased over time in TACT compared
to TACT + PD1 cells, was specifically enriched for genes in
Mitochondrial Protein Complex (including ATP5G1,
CHCHD3, COX8A, DNA2, NDUFAB1, NDUFB3,
NDUFB7, PPIF, TIMM22, TIMM23, TOMM40, TOMM40L
and UQCRC2), as well as in 27 transcripts of other
mitochondrial-related profiles (Fig. 4b). This finding sug-
gests that genes involved in mitochondrial structure and
function tend to be upregulated in TACT rather than TACT+
PD1 cells.
STEM also identified profile B, which included tran-
scripts whose expression decreased with time in TACT
relative to TACT + PD1 cells (Fig. 4a). Profile B was
enriched in GO categories related to transmembrane re-
ceptors and ion binding activities (Additional file 13:
Table S5), but none of these genes was significant after
multiple comparison correction.
Using qPCR in an independent set of samples, we
validated the differential expression of a series of mito-
chondrial genes (Fig. 4c), including HSPA9 (chaperone),
CHCHD3, CHCHD10 and PHB (cristae morphogenesis),
and MIEF1, MTFP1 and MTFR2 (mitochondrial fission);
repression of these genes was PD-1 dose-dependent
(Additional file 14: Figure S8). Consistent with their
transcriptomic upregulation, CHCHD3, CHCHD10
and MTFR2 protein levels were increased in TACT
compared to TACT + PD1 cells, as detected by immuno-
blot (Fig. 4d, e). TACT cells also showed a general
tendency to upregulate other mitochondrial proteins
such as the chaperone HSP60 and the fatty acid beta-
oxidation protein HADHA, although variability among
donors precluded significance. Expression of the mito-
chondrial respiratory chain proteins NDUFA9 (com-
plex I), SDH-B (complex II), CORE II (complex III)
and β-F1ATPase (complex V) showed no statistical
difference between TACT, TACT + PD1 and TCTRL cells,
although NDUFA9 tended to be downregulated in
TACT cells. We could not analyze expression differences in
complex IV (cox-IV and cox8A) due to deficient antibody
function or protein insolubility.
PD-1 reduces mitochondrial number but does not affect
dynamics
We analyzed whether different treatments influenced
cell mitochondrial mass. HSP60 is a marker of mito-
chondrial biogenesis [26]. Consistent with the tendency
to HSP60 downmodulation in TACT + PD1 cells, mito-
chondrial number was significantly reduced in TACT +
PD1 compared to TACT cells, as determined by direct
counting (Fig. 5a; Additional file 15: Figure S9A-C),
relative mtDNA quantity (Fig. 5b), or MitotrackerGreen
staining (Fig. 5c, d). In contrast, mitochondrial mass was
statistically unchanged between TACT and TCTRL cells
(Fig. 5a-d). As for ΔΨm, cell pre-incubation with PD-L1
reduced mitochondrial mass, which was not reversed
after their re-stimulation with TACT beads (Fig. 5e).
Mitochondrial morphology and number in T cells is
influenced dynamically by the processes of fusion and
fission [26]. PD-1 stimulation downregulated mRNA and
protein levels of MTFR2 (Fig. 4c-e), a mitochondrial fis-
sion promoter [28]. We thus measured mitochondrial
interconnectivity and shape from confocal micrographs
of aconitase 2-stained TCTRL, TACT and TACT + PD1 cells
(Fig. 5f ). We found no differences in mitochondrial cir-
cularity, a criterion related to fission/fusion events [29],
in the cell types analyzed (Fig. 5g). Moreover, we de-
tected no changes associated to cell treatment in mRNA
or protein levels of OPA-1 or DRP-1 (Fig. 5h-j), two
master regulators of mitochondrial fusion and fission
[26]. Although PD-1 downmodulates MTFR2, it thus
seems insufficient to substantially affect mitochondrial
dynamics. In a very small number of TACT + PD1 cells, we
found discrete mitochondria engulfed by double-
membrane structures that resembled autophagosomes
(Additional file 15: Figure S9D). Nevertheless, we de-
tected no differential expression of mitophagy-associated
genes in TACT + PD1 cells (not shown).
PD-1 decreases the number and length of mitochondrial
cristae
Although several reports linked PD-1 to functional mito-
chondrial impairment [15, 17–19], the structural
changes in mitochondria from PD-1-stimulated CD8+ T
cells have not been described in detail. PD-1 downregu-
lated two genes, CHCHD3 (also termed Mic19) and
CHCHD10 (Mic14; Fig. 4d, e), which form part of the
mitochondrial contact site and MICOS [30]. In mamma-
lian cells, the MICOS is a multimeric complex com-
posed of nine known subunits and putative interactors,
which links the inner boundary to the outer mitochon-
drial membranes and stabilizes cristae junctions [30].
Ultrastructural analyses showed clear differences in
the organization of the inner mitochondrial membrane
and cristae (Fig. 6a). Mitochondria from TACT cells had a
large number of tight cristae, with a parallel-oriented
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lamellar profile (Fig. 6a). This contrasted with the loose
vesicular profile of cristae in TCTRL cells. TACT + PD1 cell
mitochondria also had some swollen cristae, although
they did not show the clear vesicular profile observed in
TCTRL cells (Fig. 6a); this is consistent with the loss of
respiratory capacity and transcriptomic downregulation
of structural proteins. Moreover, TACT + PD1 cell mito-
chondria often lacked visible cristae (Fig. 6a). The per-
centage of mitochondria without cristae was significantly
larger in TACT + PD1 than in TACT cells (Fig. 6b).
Fig. 4 Validation of changes in expression of mitochondrial-related genes after PD-1 ligation. a STEM clusters of expression profiles in TACT and
TACT + PD1 cells. Only significant profiles are shown, ordered by p value (bottom left). The line in each STEM cluster represents the average
temporal expression profile for the genes assigned to the cluster. The number of genes in each profile is indicated (top right). b Scatter plot
showing GO terms of STEM profiles A, E and F, represented as circles and clustered according to semantic similarities as determined by REViGO.
Circle area is proportional to the significance of GO term overrepresentation; color indicates the log10 of the corrected p value for enrichment. c
Time-course variation of the relative quantity (Rq) of indicated transcripts in TCTRL, TACT, and TACT + PD1 cells isolated from independent donors
(n ≥ 3). d Representative immunoblots for proteins in CD8+ T cells stimulated as indicated (n ≥ 3 donors). e Densitometric analysis of
immunoblots as in d. The Rq was calculated as the ratio between each protein and β-actin, taking the value for TCTRL cells as reference. For C and
E, data are mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, using two-way ANOVA with Bonferroni post-test (c) or Kruskal-Wallis with Dunn’s
post-hoc test for multiple comparisons (e); only significant differences are indicated
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Although TCTRL cells also had a larger number of mito-
chondria without cristae than TACT cells (Fig. 6b), the
differences were not significant (p = 0.14; Fisher’s exact
test). The number of cristae per mitochondrion and the
length of these cristae was significantly reduced in TACT+
PD1 compared to TACT cells (Fig. 6c, d). The results suggest
that PD-1-induced downmodulation of these MICOS-
associated proteins affect cristae organization.
We tested whether PD-1-induced CHCHD3 downreg-
ulation is responsible for the dysfunctional state of
mitochondria. Purified, activated CD8+ T cells were
transduced with lentiviruses encoding control or
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Fig. 5 PD-1 stimulation reduces the number of mitochondria but does not affect mitochondrial dynamics. a Number of mitochondria per cell as
determined by direct counting from transmission electron microscopy images (n ≥ 83 cells/condition). Results are the average of counting by two
independent observers, one of them blind to the experiment. b Relative mitochondrial DNA quantity determined by qPCR (n = 3). c
Representative histogram of TCTRL, TACT, and TACT + PD1-stimulated cells (48 h) stained with the MitoTracker Green probe. d Quantification of mean
fluorescence intensity from cells as in c (n = 7 donors). e Quantification of MitoTrackerGreen mean fluorescence intensity in TACT and pre-treated
TACT + PD1 cells restimulated with TCTRLand TACT beads (n = 3). f Representative confocal images of TCTRL, TACT, and TACT + PD1 cells stained with
aconitase-2. g Quantification of mitochondrial circularity, determined from confocal images as in e using ImageJ software (n ≥ 31 cells/condition).
h Quantification of OPA-1 and DRP-1 mRNA levels in TACT and TACT + PD1-stimulated cells. Values were normalized to those from TCTRL cells. i
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Student’s t-test (e); * p < 0.05, ** p < 0.01, n.s., not significant
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CHCHD3 short hairpin (sh)RNA; transduction efficiency
was 11–53%. CHCHD3-shRNA effectively downregu-
lated CHCHD3 mRNA and protein levels at 48 h post-
transduction (Fig. 6e, f ). Transduced cells were then
reactivated, and mitochondrial polarization and IFNγ
production analyzed in shRNA-expressing cells (gated
by GFP co-expression). CHCHD3 silencing caused a
significant reduction in the polarization of mitochondria
(Fig. 6g) and in IFNγ production (Fig. 6h), indicating
that downregulation of a single MICOS-associated pro-
tein is sufficient to produce mitochondrial dysfunction
and to impair T cell activation.
Alterations in mitochondrial cristae are associated with
increased supercomplex assembly
Individual respiratory chain complexes can be organized
in quaternary supramolecular structures termed super-
complexes (RCS) [31, 32]. These RCS reside in the inner
mitochondrial membrane, and establish an efficient
proton gradient for complex V to synthesize ATP [33].
Although the precise RCS arrangement is largely
unknown, high-resolution structural models of the
mammalian respirasome have been described [34–37].
Since RCS are highly enriched in the cristae membrane
[31, 32] and their formation/stability is linked to cristae
shape [38], we tested whether the morphological changes
in the TACT+ PD1 cell cristae affected RCS formation. To
our surprise, we found greater enrichment of RCS con-
taining complexes I and III in mitochondrial membranes
of TACT+ PD1 and TCTRL than of TACT cells (Fig. 7a-d); in
contrast, complex III dimers were represented equally in
all cell types (Fig. 7a-d).
We searched our RNA-seq data for differentially regu-
lated genes that could explain the increased RCS forma-
tion or stability in TACT + PD1 and TCTRL cells, focusing
on the co-chaperone MCJ (methylation-controlled J
protein; also termed DnaJC15), which is described as a
negative regulator of RCS formation/stability in CD8+ T
cells [39]. We found time-dependent MCJ/DnaJC15
mRNA upregulation in TACT compared to TACT + PD1
and TCTRL cells (Fig. 7e).
Discussion
Reactivation of tumor-specific T cells through PD-1/PD-
L1 axis blockade has emerged as a prominent immuno-
therapeutic option for many cancers. Little is known of
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Fig. 6 PD-1 reduces the number and length of mitochondrial cristae. a Representative micrographs showing magnified mitochondria from TCTRL,
TACT, and TACT + PD1-stimulated cells (48 h). b-d Percentage of mitochondria without cristae (b), average number of cristae per mitochondrion in
each cell (c), and length of cristae in each mitochondrion (d) in CD8+ T cells stimulated for 48 h, as indicated. e Relative CHCHD3 mRNA levels in
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+ T cells. Data are mean ± SEM (n = 3). f Representative immunoblot showing CHCHD3 protein levels
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+ T cells showing polarized mitochondria, as determined by
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222 (TACT + PD1) mitochondria analyzed; for c, n = 17 (TCTRL), 23 (TACT) and 33 (TACT + PD1) cells. * p < 0.05, ** p < 0.01, *** p < 0.001, one-way ANOVA
with Bonferroni’s post-test (b-d) or two-tailed paired Student’s t-test (e, g-h)
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the inhibitory signals transduced by PD-1 that hinder T
cell anti-tumor activity. Several reports defined genome-
wide transcriptional programs and the underlying
molecular circuitry in exhausted CD8+ T cells, based on
lymphocytes isolated from animals infected with viruses
that induce exhaustion [40, 41], or from the tumor
microenvironment [15, 19, 42]. Since the exhaustion
program is not mediated exclusively by PD-1 signaling
[43], the genetic programs identified cannot be ascribed
entirely to PD-1 activity in these cells. Our system was
designed to define specific genetic programs regulated
after PD-1 engagement, constituting an ideal method to
identify signaling pathways controlled by this inhibitory
receptor. Principal component analysis and hierarchical
clustering showed clear commonalities in the transcrip-
tional programs of resting and PD-L1-stimulated cells at
6 h. In contrast, expression profiles of TACT + PD1 cells
stimulated for 24 and 48 h segregated from that of
resting cells. Our data for human CD8+ T cells thus
indicate that PD-1 elicits a unique, time-dependent
transcriptomic program that differs from that in resting
T cells. Further research is warranted to study the
potential of these PD-1-induced/repressed genes in
the inhibition of T cell effector function.
A set of 1651 genes showed significant divergence of
expression between TACT and TACT + PD1 cells, although
only 578 passed the FDR correction. Signaling pathway
enrichment analyses indicated metabolism as the process
with the largest number of genes with differing expres-
sion between these conditions. From the metabolic
pathways inferred to be targeted, we showed that PD-1
significantly reduced CD8+ T cell capacity to switch on
glycolysis and mitochondrial respiration (determined by
reduced basal and maximal OCR) following activation
using glucose as a substrate. We nonetheless found that
the OCR/ECAR ratio was significantly higher in TACT +
PD1 than in TACT cells, as reported for PD-1-stimulated
CD4+ T cells [16, 44]. Glycolysis inhibition in PD-1-
stimulated cells can be explained by the reported activa-
tion of the phosphatase PTEN and subsequent
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downmodulation of the AKT/mTOR pathway, down-
stream of PD-1 [20]. PD-1-mediated inhibition of basal
and maximal respiration rates could be a result of re-
duced expression and/or decreased activity after covalent
modification of respiratory chain proteins by phosphor-
ylation [45–47].
Our results also suggest that metabolic changes in-
duced by PD-1 are not simply the consequence of PD-1
inhibitory activity on T cell activation. Indeed, using
palmitate as a substrate, we found that FAO-dependent
OCR was higher in TACT + PD1 than in resting (TCTRL)
cells. This FAO elevation was associated to a time-
dependent increase in CPT1A expression specifically in
TACT + PD1 cells. Moreover, relative proton leak was also
lower in TACT + PD1 than in TACT or TCTRL cells, a
phenotype reported for memory T cells, which are
characterized by efficient mitochondrial respiration [48].
These data suggest that PD-1 shapes CD8+ T cell metab-
olism similar to long-lived cells, and provides a mechan-
istic explanation for the long-lived characteristics of
tumor-infiltrating lymphocytes (TIL) in a metabolically
insufficient tumor microenvironment.
Our study showed that mitochondrial number and
function (impaired ΔΨm) were restrained in TACT + PD1
cells. It is difficult to assess which of these two alter-
ations is more important for explaining PD-1-induced
metabolic dysfunction. It is noteworthy that the tumor
microenvironment represses mitochondrial biogenesis
[15], whereas 4-1BB costimulation increases mitochon-
dria numbers in CD8+ T cells [49]; our data thus concur
with the hypothesis that variation in mitochondria
number might be a regulatory target for co-stimulatory
and inhibitory receptors. RNA-seq data showed differen-
tial expression between TACT + PD1 and TACT cells of 84
genes coding for mitochondrial proteins. Among these,
we found mitochondria biogenesis markers such as
HSP60, and some fusion/fission regulators such as
MTFP1 and MTFR2, which were validated as downmo-
dulated in PD-1-stimulated cells at both transcriptomic
and protein levels. No alterations were detected between
TACT + PD1 and TACT cells in mitochondria circularity
and interconnectivity, two criteria related to fusion/fis-
sion processes [29]. Expression of OPA-1 and DRP-1,
two major regulators of mitochondria fusion/fission
events, was also unaltered by PD-1 engagement. We
found some images resembling mitophagy exclusively in
TACT + PD1 cells, although mitophagy-inducing genes
were not induced in these cells. It is possible that the
moderate reduction of mitochondria number in TACT +
PD1 cells might be a sum of discrete events.
Neither the PD-1-induced ΔΨm inhibition nor mito-
chondria number reduction can be rescued by PD-1
washout. These results coincide with previous reports
indicating that repression of mitochondrial activity in
the tumor microenvironment cannot be rescued by PD-
1 blockade [15]. There is, in fact, a heritable epigenetic
mechanism that drives T cell exhaustion, which is not
completely reversed by anti-PD-1 blockade [50]. A
mechanistic explanation for our results might thus be
that PD-1 engagement caused epigenetic reprograming
of CD8+ T cells, which led to irreversible functional al-
teration of the mitochondria. Further research is needed
to verify this hypothesis. The irreversibility of mitochon-
dria function as well as the preferential use of FAO in
TACT + PD1 cells thus suggest that PD-1 engagement
induces a metabolic program different from that of
resting T cells.
Ultrastructural analyses also revealed notable changes
in inner mitochondrial membrane organization in
TACT + PD1 cells, with a severe reduction in cristae/mito-
chondrion length and number, or even in their complete
loss. In lung cancer patients, mitochondria from TIL
with high PD-1 levels show fewer and shorter cristae
than those in TIL with low or no PD-1 expression [19].
The mitochondrial cristae phenotype observed here after
PD-1 engagement appears to correspond to a true defect
of cytotoxic lymphocytes exposed in vivo to PD-1
stimulation.
CHCHD3 is an important regulator in the
organization and stability of the MICOS complex, as it
links the inner and outer mitochondrial membranes
through interaction with SAM50 [30]. Our analysis
indicated consistent downregulation of two MICOS
complex proteins, CHCHD3 and CHCHD10. Given the
low transfection efficiency of primary CD8+ T lympho-
cytes, we were unsuccessful in simultaneously silencing
CHCHD3 and CHCHD10. In yeast, the soluble
CHCHD3 protein functions as the key component in
directing the inner membrane distribution of each
MICOS subcomplex [51]. We therefore postulated that
CHCHD3 silencing would be sufficient to reproduce the
cristae formation defects observed in PD-1-stimulated
cells. CHCHD3 silencing indeed recapitulated several of
the PD-1-induced dysfunctions in CD8+ T cells, such as
the decline in mitochondrial depolarization and the re-
duction in IFNγ production. Given the low transduction
efficiency of the siRNA, however, we were unable to
assess morphological alterations in mitochondrial cristae
of CHCHD3 silenced CD8+ T cells in our system.
CHCHD3 silencing in HeLa cells nonetheless leads to
notable changes in cristae morphology and even to their
loss in most cells [51].
The presence of RCS has been demonstrated in many
tissues and cells, including T cells [39]. These RCS place
individual complexes together, which increases electron
transfer efficiency in the respiratory chain and reduces
ROS production. The primary function of MICOS is to
stabilize, position, and control the copy number of
Ogando et al. Journal for ImmunoTherapy of Cancer           (2019) 7:151 Page 14 of 17
 o
n
 M
arch 30, 2020 by guest. Protected by copyright.
http://jitc.bmj.com/
J Im
m
unother Cancer: first published as 10.1186/s40425-019-0628-7 on 13 June 2019. Downloaded from
 
cristae junctions to organize the inner membrane into
an efficient respiratory machine [51]. Indeed, cristae
remodeling by OPA1 depletion affects RCS formation
and decreases respiratory efficiency [38]. We anticipated
that the reduction in OCR and ΔΨm in addition to the
dysmorphic cristae in TACT + PD1 cells might be linked to
impaired RCS formation. BN-PAGE analyses neverthe-
less showed that complex I- and III-containing RCS
were increased in TACT + PD1 compared with TACT cells.
RCS were also increased in TCTRL compared with TACT
cells, although cristae were also defective in TCTRL cells.
The increased RCS assembly in TACT + PD1 and TCTRL
cells might be a compensatory mechanism to guarantee
mitochondrial respiration following severe ultrastruc-
tural disorganization of the inner membrane. The re-
duced complex-I-containing RCS assembly in TACT cells
could be related to upregulation of the co-chaperone
MCJ/DnaJC15, a negative regulator of RCS levels in
cardiomyocytes and CD8+ T lymphocytes [39].
Conclusions
Several studies underlined the importance of metabolic
sufficiency in the initiation and maintenance of anti-
tumor immunity [15, 44], and chemicals that enhance
mitochondrial metabolism synergize with PD-1 blockade
therapy to reduce tumor growth in mice [18]. Our stud-
ies highlight mitochondria as the main targets of PD-1
inhibitory activity, causing metabolic rewiring to FAO as
well as apparently irreversible mitochondrial dysfunc-
tions that are not simply the consequence of inhibition
of the T cell activation program. We also found that
structural alterations of the cristae network in PD-1-
engaged or resting T cells unexpectedly triggered RCS
formation. A major challenge will be to design strategies
to restore the function of these newly identified elements
downstream of PD-1 to reinvigorate anti-tumor immune
responses in vivo.
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